Kalaris Therapeutics (KLRS) Other Working Capital Changes (2025 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Other Working Capital Changes of -$37000.0 for Q1 2026, up 62.24% quarter-over-quarter from -$98000.0 in Q4 2025.
Kalaris Therapeutics (KLRS) Other Working Capital Changes (2025 - 2026) Analysis & Trends
Kalaris Therapeutics' Other Working Capital Changes history runs 2 years deep, the most recent figure standing at -$37000.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes rose 102.39% year-over-year to $34000.0; the TTM figure through Mar 2026 stood at -$356000.0 (up 64.82% YoY), while the FY2025 annual figure was -$1.8 million, down 325.4% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at -$37000.0, up from -$98000.0 in the prior quarter.
- The five-year high for Other Working Capital Changes was $3.3 million in Q3 2022, with the low at -$3.2 million in Q2 2023.
- The 5-year median for Other Working Capital Changes is $8000.0 (2024), against an average of -$209352.9.
- The sharpest annual moves came in 2022 and 2025: Other Working Capital Changes sank 1274.23% in 2022, then surged 25000.0% in 2025.
- Kalaris Therapeutics' Other Working Capital Changes stood at $1.2 million in 2022, then slumped by 355.66% to -$3.0 million in 2023, then jumped by 124.59% to $733000.0 in 2024, then tumbled by 148.7% to -$357000.0 in 2025, then surged by 109.52% to $34000.0 in 2026.
- Business Quant data shows KLRS's Other Working Capital Changes at $34000.0 in Q1 2026, -$357000.0 in Q4 2025, and -$2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - |
| 10 | Kalaris Therapeutics | 97.57 Mn | 97.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11,000.00 |
| Jun 30, 2026 | -11,000.00 |
| Jun 30, 2026 | -11,000.00 |
| Mar 31, 2026 | -37,000.00 |
| Mar 31, 2026 | -37,000.00 |
| Mar 31, 2026 | -37,000.00 |
| Dec 31, 2025 | -98,000.00 |
| Dec 31, 2025 | -98,000.00 |
| Dec 31, 2025 | -98,000.00 |